Atlas Trials

Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC

Clinical trial NCT04826679 · UNKNOWN

Trial details

NCT number
NCT04826679
Sponsor
Sun Yat-sen University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Head and Neck Squamous Cell Carcinoma
Start date
2021-04-01
Primary completion
2023-04-01
Enrollment
53

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.